These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23041081)

  • 1. [Menopause and cardiovascular risk].
    Dessapt AL; Gourdy P
    J Gynecol Obstet Biol Reprod (Paris); 2012 Nov; 41(7 Suppl):F13-9. PubMed ID: 23041081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Historical perspective of hormone replacement therapy].
    Chanson P
    Rev Prat; 2005 Feb; 55(4):369-75. PubMed ID: 15828614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Menopause in 2004: "hormone replacement therapy" is not what it used to be anymore].
    Azoulay C
    Rev Med Interne; 2004 Nov; 25(11):806-15. PubMed ID: 15501350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors.
    Tikkanen MJ
    Maturitas; 1996 Mar; 23(2):209-16. PubMed ID: 8735358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular pharmacology of hormone replacement therapy.
    Rosano GM; Panina G
    Drugs Aging; 1999 Sep; 15(3):219-34. PubMed ID: 10503814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type and route of estrogen administration.
    Stevenson JC
    Climacteric; 2009; 12 Suppl 1():86-90. PubMed ID: 19811249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
    Koledova VV; Khalil RA
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
    L'Hermite M
    Climacteric; 2013 Aug; 16 Suppl 1():44-53. PubMed ID: 23848491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative.
    Lukes A
    J Manag Care Pharm; 2008 Apr; 14(3 Suppl):7-13. PubMed ID: 18439061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Attitudes toward estrogen replacement therapy. Study conducted on a sample population of women attending an ambulatory care center for the treatment of menopause].
    Perrone G; Capri O; Borrello M; Galoppi P
    Minerva Ginecol; 1993 Dec; 45(12):603-8. PubMed ID: 8139786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The metabolic syndrome in postmenopausal women. Clinical implications].
    Zárate A; Basurto L; Hernández M
    Gac Med Mex; 2003; 139(6):625-8. PubMed ID: 14723060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?
    Rosano GM; Vitale C; Fini M
    Ann N Y Acad Sci; 2006 Dec; 1092():341-8. PubMed ID: 17308159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sex hormone replacement following menopause--for all women? A plea for prevention using estrogens and gestagens].
    Nocke W
    Ther Umsch; 1995 Oct; 52(10):693-704. PubMed ID: 7482382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormones and cardiovascular health in women.
    ESHRE Capri Workshop Group
    Hum Reprod Update; 2006; 12(5):483-97. PubMed ID: 16807276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hormone replacement therapy: practical aspects].
    Sonigo C; Dray G; Chabbert-Buffet N
    J Gynecol Obstet Biol Reprod (Paris); 2012 Nov; 41(7 Suppl):F3-12. PubMed ID: 23062744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy.
    Davison S; Davis SR
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2470-8. PubMed ID: 12788842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there any rationale for prescribing hormone replacement therapy (HRT) to prevent or to treat osteoarthritis?
    Reginster JY; Kvasz A; Bruyere O; Henrotin Y
    Osteoarthritis Cartilage; 2003 Feb; 11(2):87-91. PubMed ID: 12554124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of the month. Benefit/risk balance of postmenopausal estrogen-progestin treatment in peril in the Women's Health Initiative study: practical attitude of the clinician].
    Gaspard U; van den Brûle F; Pintiaux A; Foidart JM
    Rev Med Liege; 2002 Aug; 57(8):556-62. PubMed ID: 12405030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.